Bevacizumab (Anti-VEGFA)

Human IgG1 kappa

Flow cytometric analysis of 1X10⁶ HeLa cells with Bevacizumab (HY-P9906A, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

Immobilized VEGF165 Protein, Human (HY-P7110A) can bind Bevacizumab. The EC₅₀ for this effect is 5.34 ng/mL.

Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Dec 24;10(1):417. [Abstract]

Customer Validation
Treatment of PC9-BM LCN2-high BM-bearing mice with SH4-54 (10 mg/kg, intraperitoneally, twice per week), Bevacizumab (10mg/kg, intraperitoneally, twice per week), or a combination of both significantly suppressed tumor progression and prolonged overall survival.

Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

Customer Validation
Atezolizumab (4 mg/kg; i.v.) + Bevacizumab (1 mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Collected tumor tissues of mice at the end of treatment in different groups.

Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

Customer Validation
Atezolizumab (4mg/kg; i.v.) + Bevacizumab (1mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45⁺ cells), anti-CD68/CD80-stained macrophages (gated on CD45⁺ cells),anti-HLA-DR/CD11c-stained DCs (gated on CD45⁺ Lin-1^- T cells), and anti-CD3/CD8-stained T cells (gated on CD45⁺ cells) in tumor tissues after different treatments (n = 5 independent mice).

Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069. [Abstract]

Customer Validation
Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) significantly reversed the upregulatory effect of TQHXD and HXHY on VEGFA protein in MCAO rats.

Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069. [Abstract]

Customer Validation
Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) effectively antagonized the inherent pro-angiogenic effects of TQHXD and HXHY in MCAO rats.

Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: J Clin Oncol. 2024 Oct 30:JCO2401266. [Abstract]

Customer Validation
Tumor-bearing mice were treated with vehicle, Onvansertib, and/or Bevacizumab (intraperitoneally, 5 mg/kg for SW620 and HCT116, 1 mg/kg for LoVo, twice a week) for 30-33 days.

Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798. [Abstract]

Customer Validation
Transwell assays showing that Bevacizumab (200 ng/mL, 12 h) failed to inhibit the migration of HUVECs treated with recombinant PTN protein. Unpaired t test; **, P < 0.01; ****, P <0.0001.

Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798. [Abstract]

Customer Validation
Tube formation assays showed that Bevacizumab (200 ng/mL) failed to inhibit the tube formation of HUVECs induced by recombinant PTN protein.Unpaired t test; ***, P <0.001; ****, P <0.0001.

Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar;21(3):619-638. [Abstract]

Customer Validation
VEGFA IHC staining in control and ATL-I (80 μM or 160 μM)-treated Matrigel plugs. Quantification of vegfa-positive cells. Scale bar: 100 μm. In the present set of experiments, Bevacizumab (50 ng/ml) was used as the positive control.